Xylem Q3 2026: orders +10% organic, sales flat; GAAP EPS +34% leans on one-offs, guidance cut

Xylem's third quarter of 2026 looks strong on the headline and soft underneath. Revenue fell 3.0% to $2,201 million, and was flat organically (organic means stripping out currency swings and businesses bought or sold; most of the reported drop is the international metering business sold in May). Diluted EPS jumped 34% to $1.25. But the operating business earned about what it did a year ago: adjusted operating income was $428 million against $429 million, and adjusted pretax income fell 3.7%. Orders were the bright spot, up 10% organically. Management cut its full-year revenue and EPS guidance and announced plans to sell two businesses and reorganise into three segments from January 2027.

The numbers

Source: Xylem's Q3 2026 earnings release (8-K Exhibit 99.1, filed October 27, 2026). The full 10-Q is not filed yet, so the release gives no segment profit, no backlog figure and no management explanation of what drove each segment. Those gaps are noted below. "Adjusted" figures are Xylem's own non-GAAP measures. They exclude restructuring and realignment costs, amortization of acquired intangible assets (the accounting write-down of customer relationships and technology bought in deals such as Evoqua), gains or losses on business sales, special charges and tax-related special items. A basis point (bp) is one-hundredth of a percentage point.

Segments: orders up, sales mostly not

Applied Water (pumps for buildings and industry) was the only segment that grew: revenue up 9% organically and orders up 15%. The release points to "high-growth industry verticals, including data centers and microelectronics" as where Xylem is "already seeing momentum." The 10-Q will say how much of this came from data centers.

Measurement & Control Solutions (smart water meters and analytics) reported a 16% revenue drop, but $68 million of the $86 million decline is the international metering business sold in May. On a like-for-like basis revenue fell 5%. Orders, though, rose 30% organically, the strongest of any segment.

Water Infrastructure (pumps and treatment for moving and cleaning water) slipped about 1% organically on both revenue and orders. It is the business most tied to municipal and capital-project budgets, and the release's line about project timing and "more cautious spending" fits what this segment shows.

Water Solutions and Services (outsourced treatment, rentals and services, largely the former Evoqua business) fell 2% organically. Its revenue of $631 million was almost the same as a year ago.

What the headline numbers hide

Nearly all of the 34% GAAP EPS rise came from items Xylem itself excludes from "adjusted." Pretax income rose $68 million. About $32 million of that came from a smaller loss on business sales ($5 million vs $37 million). Another $33 million came from refunds of tariffs paid under the International Emergency Economic Powers Act (IEEPA), which were booked as a reduction in expense. Restructuring and realignment costs also fell to $14 million from $31 million. The total gap between GAAP and adjusted EPS shrank from $0.44 to $0.19. Without the tariff refund, GAAP operating margin would have been about 16.0% rather than 17.5% (our calculation: $352 million on $2,201 million of revenue). That figure is still up from 14.7%, mostly because of the lower one-off charges.

On Xylem's own adjusted basis, profit before tax fell. Adjusted operating income was flat at $428 million. Interest expense rose to $21 million from $6 million after about $1 billion of new long-term debt this year, so adjusted pretax income fell to $413 million from $429 million (−3.7%). Adjusted net income still rose 0.9% to $336 million because the adjusted tax rate dropped to about 19.4% from 22.6% (our calculation from the reconciliation: $80 million of tax on $413 million, against $97 million on $429 million).

Buybacks did the rest. Diluted shares fell 4.5% to 233.0 million. At last year's share count, $336 million of adjusted net income would be about $1.38 per share, roughly +1% rather than +5%. Xylem spent $1,580 million on buybacks in the first nine months, against $14 million a year earlier. About $337 million of that was in Q3 (the $1,580 million year-to-date figure minus the $1,243 million first-half figure in the Q2 10-Q), alongside about $100 million of dividends derived the same way. The buyback was partly funded with debt. Net debt (borrowings minus cash) rose to about $2.19 billion at September 30 from about $0.46 billion at the end of 2025. The company also spent about $424 million on acquisitions in the quarter ($425 million year to date against $1 million at mid-year). The release doesn't name them, but it does mention debt for a "pending Cornell Pump and Roper Pump acquisition."

Margins did improve. Gross margin rose 230 bp to 41.2%, and the adjusted EBITDA margin (earnings before interest, tax, depreciation and amortization, as a share of revenue) rose 70 bp to 23.9%. The release credits "productivity savings and strong price realization," which outweighed "inflation, lower volumes, and mix." In dollars, though, adjusted EBITDA was $527 million in both years. The margin rose because revenue shrank, not because profit grew. If the tariff refund was booked in cost of revenue like Q2's, it accounts for about 1.5 points of the gross-margin gain. The release doesn't say where it was booked.

Cash flow was fine for the quarter but is behind the full-year target. Q3 operating cash flow was about $331 million against $288 million of net income, or 115%. (These figures are derived from the nine-month statement minus the first half in the Q2 10-Q. The release's cash-flow table is headed "June 30," but its figures are the nine-month ones.) That was still down from about $360 million a year ago. Free cash flow (operating cash flow minus capital spending) was $461 million for nine months, or 6.9% of revenue. Hitting the newly trimmed ~10.2% full-year target implies roughly $450 million in Q4 alone. Receivables are part of the reason: they rose to $1,965 million from $1,759 million at year-end (+11.7%) while nine-month revenue was flat, and long-term receivables tied to project work absorbed another $147 million of cash.

On balance the quarter is flattered: GAAP EPS rose 34%, but adjusted pretax income fell 3.7%, and a tariff refund, smaller deal losses, a lower tax rate and a 4.5% smaller share count account for the growth.

Takeaway: Xylem is holding margins by cutting costs while sales stall, and it is turning flat profit into EPS growth with debt-funded buybacks. The 10% organic order growth is the one figure that points to sales growth ahead. The guidance cut says management doesn't expect that to show up in revenue this year.

Did last quarter's read hold up?

Our Q2 report named three things to watch. The results were mixed.

• Would the large Water Solutions and Services contract start turning into revenue? Not yet. That segment's revenue fell 2% organically.
• Would Measurement & Control Solutions orders recover from an 85% book-to-bill? Yes, clearly. Orders rose 30% organically and book-to-bill was 116%. Revenue still fell 5% organically.
• Would free cash flow catch up to the 10.2–11.0% target? Partly. The nine-month free cash flow margin improved to 6.9% from 4.9% at mid-year, but the target is now "approximately 10.2%," the bottom of the old range.

We also said EPS was "increasingly supported by debt-funded buybacks." Q3 bears that out more strongly: adjusted pretax income fell, and the share count fell 4.5%.

Outlook

Xylem's new 2026 guidance:

• Revenue: about $8.95 billion, −1% reported and flat organically (was +2% and +2–3%).
• Adjusted EBITDA margin: about 23.2%, 100 bp above 2025.
• Adjusted EPS: $5.40–$5.45 (was $5.55–$5.70).
• Free cash flow margin: about 10.2% (was 10.2–11.0%).

What this implies for Q4 (our arithmetic from the guidance and nine-month figures):

• Revenue of about $2,288 million, roughly 4.5% below Q4 2025's $2,397 million.
• Adjusted EBITDA of about $568 million, a margin near 24.8%, against 23.2% a year ago.
• Adjusted EPS of about $1.39–$1.44, against nine-month adjusted EPS of $4.01 ($1.11 + $1.46 + $1.44).

So the plan for Q4 is another quarter of falling sales with rising margins.

Portfolio changes. Xylem intends to divest Applied Water International and Specialty Flow Control. From January 1, 2027 it will report three segments instead of four: Treatment and Services, Flow Solutions, and Measurement and Analytics. The release gives no sale prices, timing or revenue for the businesses being sold. The 2027 segment figures won't be directly comparable with today's four segments.

Our view. The order growth is real and broad outside Water Infrastructure, and the 10-Q's backlog figure will show how much of it converts in 2027. Until it does, EPS growth rests on margins and a share count shrinking with borrowed money, while interest costs rise. Three things to watch next:

1. Whether Q4 revenue lands near the implied ~$2.29 billion.
2. Whether Water Infrastructure orders turn positive, as a read on municipal and capital-project budgets.
3. How much revenue and EBITDA the two divestitures take out of the 2027 base.